• Nuclear Medicine and Molecular Imaging
• /
• 제42권2호
• /
• pp.98-111
• /
• 2008

This review introduces advances in clinical and pre-clinical single photon emission computed tomography (SPECT) and positron emission tomography (PET) providing noninvasive functional images of biological processes. Development of new collimation techniques such as multi-pinhole and slit-slat collimators permits the improvement of system spatial resolution and sensitivity of SPECT. Application specific SPECT systems using smaller and compact solid-state detector have been customized for myocardial perfusion imaging with higher performance. Combined SPECT/CT providing improved diagnostic and functional capabilities has been introduced. Advances in PET and CT instrumentation have been incorporated in the PET/CT design that provide the metabolic information from PET superimposed on the anatomic information from CT. Improvements in the sensitivity of PET have achieved by the fully 3D acquisition with no septa and the extension of axial field-of-view. With the development of faster scintillation crystals and electronics, time-of-flight (TOF) PET is now commercially available allowing the increase in the signal-to-noise ratio by incorporation of TOF information into the PET reconstruction process. Hybrid PET/SPECT/CT systems has become commercially available for molecular imaging in small animal models. The pre-clinical systems have improved spatial resolution using depth-of-interaction measurement and new collimators. The recent works on solid state detector and dual modality nuclear medicine instrumentations incorporating MRI and optical imagers will also be discussed.

• Annals of Clinical Neurophysiology
• /
• 제22권1호
• /
• pp.37-40
• /
• 2020

Neurolymphomatosis (NL) is characterized by the infiltration of malignant lymphoma cells into peripheral nerves, nerve roots, plexuses, or cranial nerves. This is a very rare complication of mantle-cell lymphoma. Diagnosing NL is made difficult by cerebrospinal fluid cytology and bone-marrow biopsy results often being negative. NL can appear as the only sign of recurrence in a patient with a previous diagnosis of lymphoma. Here we present two cases of NL in patients with mantle-cell lymphoma diagnosed by positron emission tomography with deoxy-fluoro-D-glucose integrated with computed tomography.

• Nuclear Medicine and Molecular Imaging
• /
• 제43권6호
• /
• pp.582-587
• /
• 2009

A 59-year-old woman who was diagnosed with malignant pheochromocytoma underwent $^{18}F$-fluorodeoxyglucose positron emission tomography/computed tomography ($^{18}F$-FDG PET/CT). She had undergone left adrenalectomy for pheochromocytoma 4 years previously. Recent multiple metastatic pulmonary nodules were noted on the chest X-ray. After treatment with $^{131}I$-metaiodobenzylguanidine ($^{131}I$-MIBG) with 7.4 GBq, post-therapy $^{131}I$-MIBG scintigraphy depicted multiple distant metastases including lung, liver, abdominal para-aortic and mesenteric lymph nodes. $^{18}F$-FDG PET/CT also depicted multiple metastases in lung, liver, and abdominal para-aortic lymph nodes, but some lesions were not shown. In this case, $^{131}I$-MIBG scintigraphy found additional lesions in metastatic malignant pheochromocytoma.

• 대한방사성의약품학회지
• /
• 제1권2호
• /
• pp.80-87
• /
• 2015

Carbon-fluorine (C-F) bonds have been found ubiquitously in pharmaceuticals, radiopharmaceuticals, agrochemicals, and material science due to their unique properties such as thermal and oxidative stability and lipophilicity to improve bioavailability. For the past five years, there have been significant advances in F-18 fluorination of aromatic complex molecules combined with the development of late-stage fluorination reactions. More recently, direct incorporation of F-18 to fluorinated aromatic molecules via borylation of C-F bonds has been developed by Niwa and Hosoya. In this minireview, we will discuss the progress of C-F bondborylation of fluorinated arenes utilizing transition metal catalysts and the impact on the development of F-18 radiotracers for positron emission tomography (PET).

• Journal of the Korean Physical Society
• /
• 제73권12호
• /
• pp.1904-1907
• /
• 2018

We designed a depth-encoding positron emission tomography (PET) detector by using a bottom and side readout method with a cross-arranged scintillator array. To evaluate the characteristics of the novel detector module, we used the DETECT2000 simulation tool to perform the optical photon transport in the crystal array. The detector module consists of an $M(column){\times}N(row)$ cross-arranged crystal array composed of M/3 sub-arrays consisting of $N{\times}3$ crystals. The second column of the sub-array is arranged perpendicular to the first and the third columns. The crystal is optically coupled to the crystals of the other columns; however, the surfaces between the crystals in the same column are treated as reflectors. A $6{\times}5$ crystal array consisting of two sub-arrays was considered for proof of concept. The two multi-pixel photon counter (MPPC) arrays are coupled to the bottom and one side of the crystal array, respectively. The x-y position is determined by the bottom MPPC array, and the side MPPC array gives depth information. All pixels in the x-y plane and the z direction were clearly distinguished.

• 한국정보과학회:학술대회논문집
• /
• 한국정보과학회 2005년도 한국컴퓨터종합학술대회 논문집 Vol.32 No.1 (A)
• /
• pp.703-705
• /
• 2005

본 논문에서는 기울기 크기 기반의 3차원 영역확장 알고리즘을 사용하여 small animal PET(Positron Emission Tomography) 영상으로부터 종양을 분할하는 연구를 수행하였다. 픽셀 값의 범위가 다양하고 저해상도의 특성을 갖는 PET영상으로부터 대상영역을 정확하게 분할하기 위해서 전처리(preprocessing)과정으로 영상 픽셀값의 분포를 펼쳐줌으로써 영상의 가시화를 높이는 히스토그램 스트레칭(histogram stretching) 기법을 적용하고 대상영역과 픽셀값이 유사한 인접영역과의 경계를 찾기 위해 가우시안의 1차 미분 함수를 사용하여 계산된 기울기 크기(gradient magnitude) 기반의 3차원 영역확장(region growing) 알고리즘을 제안한다. 제안한 알고리즘은 영역확장의 결과에 가장 큰 영향을 미치는 적절한 동질성 기준의 선택으로 대상영역의 분할을 성공적으로 수행하여 일반적인 영역확장의 단점을 보완하였다.

• 대한방사성의약품학회지
• /
• 제8권1호
• /
• pp.33-37
• /
• 2022

Translocator protein (TSPO) is associated with neurodegeneration diseases, and the development of potent ligands with high affinity to TSPO was valuable study for many scientists. Specially, pyrazolo[1,5-a]pyrimidine moiety has been employed for development of new TSPO ligands with good properties. In this highlight review, the development of [¹⁸F]F-DPA as a promising TSPO ligand as PET tracer is described.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 2002년도 춘계학술대회 및 총회
• /
• pp.45-53
• /
• 2002

Positron Emission Tomography(PET) was introduced as a research tool in the 1970s and it took about 20 years before PET became an useful clinical imaging modality. In the USA, insurance coverage for PET procedures in the 1990s was the turning point, I believe, for this progress. Initially PET was used in neurology but recently more than 80% of PET procedures are in oncological applications. I firmly believe, in the 21st century, one can not manage cancer patients properly without PET and PET is very important medical imaging modality in basic and clinical sciences. PET is grouped into 2 categories : conventional(c) and gamma camera $based_{(CB)}$ PET. $_{CB}PET$ is more readily available utilizing dual-head gamma cameras and commercially available FDG to many medical centers at low cost to patients. In fact there are more $_{CB}PET$ in operation than cPET in the USA. $_{CB}PET$ is inferior to cPET in its performance but clinical studies in oncology is feasible without expensive infrastructures such as staffing, rooms and equipments. At Ajou university Hospital, CBPET was installed in late 1997 for the first time in Korea as well as in Asia and the system has been used successfully and effectively in oncological applications. Ours was the fourth PET operation in Korea and I believe this may have been instrumental for other institutions got interested in clinical PET. The fellowing is a brief description of our clinical experience of FDG CBPET in oncology.

• 대한위암학회:학술대회논문집
• /
• 대한위암학회 2004년도 제18회 추계학술대회
• /
• pp.44-44
• /
• 2004

• 대한방사성의약품학회지
• /
• 제7권2호
• /
• pp.127-131
• /
• 2021

Neuroendocrine tumor is one of popular diseases, and somatostatin receptor antagonists have been considered as promising agents for neuroendocrine tumors. Imaging of somatostatin receptor is useful approach on the diagnosis and therapy of neuroendocrine tumors. Thus, several radiolabeled somatostatin derivatives have been developed by scientists, and used for patients with neuroendocrine tumors. In particular, some radiopharmaceuticals for neuroendocrine tumors were approved by FDA. In this highlight review, the development of important radiolabeled somatostatin derivatives is described.